Evaluation of cytokines IL-1β and IL-1Ra concentration in nasal secretion in patients with acute purulent rhinosinusitis during immune therapy of β-D-glucans

Abstract

Introduction. Standard methods and medicines for treatment of acute purulent rhinosinusitis (APRS) do not possess immunomodulating activity that does not promote development of fast dynamics of the end of inflammatory process and knocking over of the basic symptoms of disease. The β-D-glucans mushrooms origin have anti-inflammatory and immunomodulating activity. However, application of these biopolymers for treatment APRS is studied insufficiently.

The aim of the study - an assessment of a distribution of functional pair of cytokines IL-1Ra and IL-1β concentrations in nasal secrets in patients with APRS against application of antibiotics in a combination with β-D-glucans.

Material and methods. Patients have been divided into 4 independent groups. Group 1 consisted of 32 healthy ones. Group 2 consisted of 24 patients with APRS before treatment. Group 3 consisted of 22 patients with APRS who received standard therapy, including antibacterial drugs and puncture of the maxillary sinuses. Group 4 consisted of 24 patients who received β-D-glucans along with standard therapy. The total duration of therapy was 10 days. IL-1Ra and IL-1β concentrations in nasal secrets were defined by enzyme-linked immunosorbent assay, ELISA.

Results. It is positioned that the qualitative visual estimation of shift of a projection of specified cytokines concentrations shows positive changes since by 10 day of treatment in group of the patients received combined therapy, the area of a projection of its concentration comes nearer to cytokines projection area in healthy people. Standard therapy does not lead to such effect, since the minimal impact on local changes of these cytokines levels.

Conclusion. Addition of a medicine containing immunomodulating component β-D-glucans to the APRS standard treatment is reasonable.

Keywords:β-D-glucans; acute rhinosinusitis; cytokines; IL-1β; IL-1Ra; immune correction therapy

For citation: Bezrukova E.V., Vorobeychikov E.V., Konusova V.G., Paschinin A.N., Simbirtsev A.S. Evaluation of cytokines IL-1β and IL-1Ra concentrations in nasal secretion in patients with acute purulent rhinosinusitis during immune therapy of β-D-glucans. Immunologiya. 2020, 41 (3): 227-34. DOI: 10.33029/0206-4952-2020-41-3-227-234 (in Russian)

Funding. The study had not sponsor support.

Conflict of interests. The authors declare no conflict of interests.

References

1. Acute rhinosinusitis: clinical recommendations. In: A.S. Lopatin (ed.). Moscow: Rossiyskoe obshchestvo rinologov, 2017: 36 p. (in Russian)

2. Krivopalov A.A. Rhinosinusitis: classification, epidemiology, etiology and treatment. Meditsinskiy sovet. 2016; 6: 22–5. (in Russian)

3. Fokkens W.J., Lund V.J., Mullol J., Bachert C., Alobid I., Baroody F., Cohen N., Cervin A., Douglas R., Gevaert P., Georgalas C., Goossens H., Harvey R., Hellings P., Hopkins C., Jones N., Joos G., Kalogjera L., Kern B., Kowalski M., Price D., Riechelmann H., Schlosser R., Senior B., Thomas M., Toskala E., Voegels R., Wang de Y., Wormald P.J. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. Asummary for otorhinolaryngologists. Rhinology. 2012; 50 (1): 1–12.

4. Ovchinnikov A.Yu., Edzhe M.A., Khon E.M., Korostelev S.A. Acute rhinosinusitis:the main misconceptions and the possibility of a standard herbal medicine. Meditsinskiy sovet. 2016; 6: 28–31. (in Russian)

5. Ryazantsev S.V., Krivopalov A.A., Eremin S.A., Zakharova G.P., Shabalin V.V., Shamkina P.A., Chufistova A.V. Topical antibacterial therapy for acute rhinosinusitis. RMZh. 2020; 4: 2–7. (in Russian)

6. Kosyakov S.Ya., Minavnina Yu.V. Place of topical steroid therapyin the thretment of acute rhinosinusitis. Meditsinskiy sovet. 2017; 16: 18–23.(in Russian)

7. The principles of etiopathogenesis therapy of acute rhinosinusitis: method. Recommendation. In: S.V. Ryazantsev (ed.). Saint Petersburg: Poliforum Grupp, 2015: 40 p. (in Russian)

8. Karpishchenko S.A., Lavrenova G.V., Shakhnazarov A.E., et al. Acute and chronic rhinosinusitis: additional opportunities of conservative treatment. Folia Otorhinolaryngologiae et Pathologiae Respiratoriae. 2018; 24 (4): 6268. (in Russian)

9. Svistushkin V.M., Nikiforova G.N., Ovchinnikov A.Yu., et al. Opportunities of non-puncture treatment of purulent rhinosinusitis. Rossiyskaya otorinolaringologiya. 2004; 3 (10): 150–2. (in Russian)

10. Referens Vidal’ 2020. Medicines in Russia. Vidal’ Rus, 2020: 1118 p. ISBN:978-5-9500273-9-0. (in Russian)

11. Iwasaki A., Medzhitov R. Control of adaptive immunity by the innate immune system. Nat. Immunol. 2015; 16 (4): 343–53. DOI: 10.1038/ni.3123.

12. Hannoodee S., Nasuruddin D.N. Acute Inflammatory Response. URL: https://www.ncbi.nlm.nih.gov/pubmed/32310543.

13. Koatz A.M., Coe N.A., Cicerán A., Alter A.J. Clinical and immunological benefits of OM-85 bacterial lysate in patients with allergic rhinitis, asthma, and COPD and recurrent respiratory infections. Lung. 2016; 194 (4): 687–97. DOI: 10.1007/s00408-016-9880-5.

14. Esposito S., Bianchini S., Bosis S., Tagliabue C., Coro I., Argentiero A., Principi N. A randomized, placebo-controlled, double-blinded, single-centre, phase IV trial to assess the efficacy and safety of OM-85 in children suffering from recurrent respiratory tract infections. J. Transl. Med. 2019; 17 (1): 284. DOI: 10.1186/s12967-019-2040-y.

15. Esposito S., Bianchini S., Polinori I., Principi N. Impact of OM-85 given during two consecutive years to children with a history of recurrent respiratory tract infections: a retrospective study. Int. J. Environ. Res. Public Health. 2019; 16 (6): E1065. DOI: 10.3390/ijerph16061065.

16. Yin M., Zhang Y., Li H. Advances in research on immunoregulation of macrophages by plant polysaccharides. Front. Immunol. 2019; 10: 145. DOI: 10.3389/fimmu.2019.00145.

17. Friedman M. Mushroom polysaccharides: chemistry and antiobesity, antidiabetes, anticancer, and antibiotic properties in cells, rodents, and humans. Foods. 2016; 5 (4): 80.

18. Camilli G., Tabouret G., Quintin J. The complexity of fungal β-glucan in health and disease: effects on the mononuclear phagocyte system. Molecules. 2016; 21 (7): 938.

19. Bashir K.M., Choi J.S. Clinical and physiological perspectives of β-glucans: the past, present, and future. Int. J. Mol. Sci. 2017; 18 (9): 84–102.

20. Jesenak M., Urbancikova I., Banovcin P. Respiratory tract infections and the role of biologically active polysaccharides in their management and prevention. Nutrients. 2017; 9 (7): 779.

21. Elsayed A., Enshasy H., et al. Mushrooms: a potential natural source of anti-inflammatory compounds for medical applications. Mediators Inflamm. 2014; 10 (1): 55–81.

22. Vetvicka V., Vetvickova J. Glucan supplementation enhances the immune response against an influenza challenge in mice. Ann. Transl. Med. 2015; 22 (2): 2305.

23. Muszyńska B., Grzywacz-Kisielewska A., Kała K., Gdula-Argasińska J. Anti-inflammatory properties of edible mushrooms: a review. Food Chem. 2018; 243: 373–81.

24. Leentjens J., Quintin J., Gerretsen J., et al. The effects of orally administered beta-glucan on innate immune responses in humans, a randomized open-label intervention pilot-study. PLoS One. 2014; 9 (9): e108794.

25. Minov J., Bislimovska-Karadzhinska J., et al. Effects of pleuran (Β-glucan from Pleurotus ostreatus) supplementation on incidence and duration of COPD exacerbations. J. Med. Sci. 2017; 5 (7): 893–8.

26. Bezrukova E.V., Vorobeychikov E.V., Konusova V.G. Increment of antibiotic therapy efficiency in acute purulent rhinosinusitis. Rossiyskaya otorinolaringologiya. 2013; 3 (64): 10–6. (in Russian)

27. Bezrukova E.V., Vorobeychikov E.V., Konusova V.G., Kurtser G.M., Simbirtsev A.S. Exploring effect of changing concentration in cytokines IL-1RA and IL-1β of nasal secretions in patients undergoing immune correction to treat chronic polypous rhinosinusitis. Immunologiya. 2019; 40 (5): 5–10.(in Russian)

28. Bezrukova E.V., Vorobeychikov E.V., Konusova V.G., Simbirtsev A.S. Changes of cytokines concentration of IL-1β and IL-1RA in chronic polyposis rhinosinusitis. Meditsinskaya immunologiya. 2019; 21 (6): 1155–62. (in Russian)

29. Patent RF No. 2450812, 20122450812 «Agent for treatment of infectious diseases of respiratory tract «Glyukaferon», 2012. (in Russian)

30. Shamtsyan M.M., Vorobeychikov E.V., Konusova V.G., Simbirtsev A.S. Immunomodulatory properties of higher basidial mushrooms. Tsitokiny i vospalenie. 2012; 11 (1): 26–37. (in Russian)

31. Borovikov V. Statistics: the art of analyzing data on a computer. For professionals. Saint Petersburg: Piter, 2001: 656 p. (in Russian)

32. Subbotina A.V., Grzhibovskiy A.M. Descriptive statistics and validation of the normality of the distribution of quantitative data. Ekologiyacheloveka. 2014; 2: 51–7. (in Russian)

33. van Bruggen R., Drewniak A., Jansen M., et al. Complement receptor 3, not Dectin-1, is the major receptor on human neutrophils for beta-glucan-bearing particles. Mol. Immunol. 2009; 47: 575–81.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)


JOURNALS of «GEOTAR-Media»